Articles by Dr. John Stehlin, as of 5/2/2001

121. Stehlin JS, Giovanella BC, et al. A phase II study of RFS (2000)-9-nitrocamptothecin in patients with advanced pancreatic cancer: a preliminary report. Intl J Oncol 14:281-831, 1999.

120. Verschraegen CF, Natelson EA, Giovanella BC, Kavanagh JJ, Kudelka AP, Freedman RS, Edwards CL, Ende K and Stehlin JS. A phase I clinical and pharmacological study of oral 9-nitrocamptothecin, a novel water-insoluble topoisomerase I inhibitor. Anticancer Drugs 9(1):36-44, Jan 1998.

119. Cao Z, Harris N, Kozielski AJ, Vardeman D, Stehlin JS and Giovanella BC. Alkyl esters of camptothecin and 9-nitro camptothecin: synthesis, in vitro pharmacokinetics, toxicity and antitumor activity. J Med Chem 41(1):31-37, Jan 1 1998.

118. Ahmed AE, Jacob S, Giovanella BC, Kozielski AJ, Liehr JG and Stehlin JS. Comparative disposition of the antineoplastic agent 9-nitrocamptothecin and the inactive isomer 12-nitro camptothecin in CASE-bearing nude mice: effect of route of administration on tissue distribution. Cancer Chemother Pharmacol; 41(1):29-36, 1997.

117. Ahmed AE, Jacob S, Giovanella BC, Kozielski AJ, Stehlin JS and Liehr JG. Influence of route of administration on [3H]-camptothecin distribution and tumor uptake in CASE-bearing nude mice: whole-body autoradiographic studies. Cancer Chemother Pharmacol 39(1-2):122-30, 1996.

116. Natelson EA, Giovanella BC, Verschraegen CF, Fehir KM, de Ipolyi PD, Harris N and Stehlin JS. Phase I clinical and pharmacological studies of 20-(S)-camptothecin and 20-(S)-9-nitrocamptothecin as anticancer agents. Ann N Y Acad Sci 803:224-30, Dec 13 1996.

115. Potmesil M, Vardeman D, Kozielski AJ, Mendoza J, Stehlin JS and Giovanella BC. Growth inhibition of human cancer metastases by camptothecins in newly developed xenograft models. Cancer Res 55(23):5637-41, Dec 1 1995.

114. Pantazis P, Hinz HR, Mendoza JT, Kozielski AJ, Williams LJ Jr, Stehlin JS and Giovanella BC. Complete inhibition of growth followed by death of human malignant melanoma cells in vitro and regression of human melanoma xenografts in immunodeficient mice induced by camptothecins. Cancer Res 52(14):3980-87,
July 15 1992.

113. Tschen, JA, Fordice DB, Reddick M and Stehlin JS. Amelanotic melanoma presenting as inflammatory plaques. J Am Acad Dermatol Sep; 27(3):464-465, 1992.

112. Coil DR, Giovanella BC, Greeff, PJ, Stehlin JS and Davis BR. An experimental model for the study of thermochemotherapy in vivo. Anticancer Res Sep-Oct; 12(5):1363-1371, 1992.

111. Verschraegen CF, Giovanella BC, Mendoza JT, Kozielski AJ and Stehlin JS. Specific organ metastases of human melanoma cells injected into the arterial circulation of nude mice. Anticancer Res 11(2):529-35, Mar-Apr 1991.

110. Giovanella BC, Hinz HR, Kozielski AJ, Stehlin JS, Silber R and Potmesil M. Complete growth inhibition of human cancer xenografts in nude mice by treatment with 20-(S)-camptothecin. Cancer Res 51(11):3052-55, June 1 1991.

109. Giovanella BC, Vardeman DM, Williams LJ Jr, Taylor DJ, de Ipolyi PD, Greeff PJ, Stehlin JS, Ullrich A, Cailleau R, Slamon DJ, Cailleau R and Gary HE. Heterotransplantation of human breast carcinomas in nude mice: correlation between successful heterotransplants, poor prognosis and amplification of the HER-2/neu oncogene. Int J Cancer 47(1):66-71, Jan 1991.

108. Giovanella BC, Stehlin JS, Wall ME, Wani MC, Nicholas AW, Liu LF, Silber R and Potmesil M. DNA topoisomerase I-targeted chemotherapy of human colon cancer in xenografts. Science 246(4933):1046-48, Nov 24 1989.

107. Heim S, Mandahl N, Arheden K, Giovanella BC, Yim SO, Stehlin JS and Mitelman F. Multiple karyotypic abnormalities, including structural rearrangements of 11P in cell lines from malignant melanomas. Cancer Genet Gytogenet 35(1):5-20, Oct 1988.

106. Stehlin JS, de Ipolyi PD, Greeff PJ, McGaff CJ Jr, Davis BR and McNary LP. Treatment of cancer of the liver. Twenty years' experience with infusion and resection in 414 patients. Ann Surg 208(1):23-35, July 1988.

104. Lockshin A and Stehlin JS. Improved tumor localization of 111in-labeled monoclonal antibody with chelator administration to host nude mice. Eur J Nucl Med 12(11):573-75, 1987.

105. Stehlin JS, Greeff PJ, de Ipolyi PD, Giovanella BC, Klein G, McGaff CJ, Davis BR, Williams LJ, Natelson EA and Anderson RF. Heat as an adjuvant in the treatment of advanced melanoma: an immune stimulant? Hou Med J 4:53-61, June 1988.

103. Lockshin A, Kozielski T and Stehlin JS. In vivo cytotoxicity assays with 111in-labeled tumor cells: comparison with [125I]iododeoxyuridine-labeled cells and effects of chelators and inoculation site. Int J Rad Appl Instrum [B]; 14(5):515-21, 1987.

102. Stehlin JS, de Ipolyi PD, Greeff PJ, Gutierrez AE, Hardy RJ and Dahiya SL. Cancer of the breast a ten-year study of partial mastectomy. Surg Gynec & Obstet 165(3):191-98, Sep 1987.

101. Kozielski T, Lockshin A, Giovanella BC and Stehlin JS. A method for prolonged, repeated infusion of nude mice. Lab Anim Sci 36(6):696-98, December 1986

Top of Page.

100. Lockshin A, Kozielski T and Stehlin JS. Prediction of anticancer activity by tumor uptake of radiolabeled monoclonal antibody. Cancer Lett 30(1):1-9, Jan 1986.

99. Lockshin A, Mendoza JT, Giovanella BC and Stehlin JS. 111indium labeling of cultured human tumor cells. Oncology 42(5):322-27, 1985.

98. Lockshin A, Giovanella BC, Mendoza JT, Warneke C and Stehlin JS. Selective cytotoxicity of 5-hydroxyuridine for human colon adenocarcinoma cells. Cancer Treat Rep 69(7-8:845-50, Jul-Aug 1985.

97. Lockshin A, Giovanella BC, de Ipolyi PD, Williams LJ Jr, Mendoza JT, Yim SO and Stehlin JS. Exceptional lethality for nude mice of cells derived from a primary human melanoma. Cancer Res 45(1)345-50, Jan 1985.

96. Lockshin A, Giovanella BC, Stehlin JS, Kozielski T, Quian C and Apperson RW. Antitumor activity and minimal toxicity of cencentrated thymidine infused in nude mice. Cancer Res 45(4):1797-802, Apr 1985.

95. Lockshin A, Giovanella BC, Vardeman DM, Mendoza JT, Quian C, Kozielski T and Stehlin JS. Effectiveness of anticancer drugs determined in nude mice inoculated with [125]5-Iodo-2'-deoxyuridine prelabeled human melanoma cells. J Natl Cancer Inst 74(4):899-903, Apr 1985.

94. Stehlin JS, Giovanella BC, Gutierrez AE, de Ipolyi PD and Greeff PJ. 15 years' experience with hyperthermic perfusion for treatment of soft tissue sarcoma and malignant melanoma of the extremities. Front Radiat Ther Oncol 18:177-82, 1984.

93. Giovanella BC, Hunter JT, Gary DW, Stehlin JS and Ledbetter J. Nude mice of different strains in parabiosis for prolonged periods of time. Exp Cell Biol 52(1-2)114-18, 1984.

92. Giovanella BC, Stehlin JS and Coil D. Human tumors heterotransplanted in nude mice and rats: a comparative study. Exp Cell Biol 52(1-2)76-79, 1984.

91. Lockshin A, Giovanella BC, Kozielski T and Stehlin JS. Determination of cytotoxicity in vivo using 111indium-labeled human tumor cells. Cancer Lett 24(2):179-85, Sep 1984.

90. Lockshin A, Giovanella BC, Quian C, Mendoza JT, Vardeman DM and Stehlin JS. Correlation of cytotoxicity with elimination of iodine125 from nude mice inoculated with prelabeled human melanoma cells. J Natl Cancer Inst 73(2):417-22, Aug 1984.

89. Lockshin A, Mendoza JT, Giovanella BC and Stehlin JS. Cytotoxic and biochemical effects of thymidine and 3-deazauridine on human tumor cells. Cancer Res 44(6):2534-39, Jun 1984.

88. Giovanella BC, Stehlin JS, Shepard RC and Williams LJ Jr. Correlation between response to chemotherapy of human tumors in patients and in nude mice. Cancer 52(7):1146-52, Oct 1 1983.

87. Rossen RD, Crane MM, Morgan AC, Giannini EH, Giovanella BC, Stehlin JS, Twomey JJ and Hersh EM. Circulating immune complexes and tumor cell cytotoxins as prognostic indicators in malignant melanoma: a prospective study of 53 patients. Cancer Res 43(1):422-29, Jan 1983.

86. Ernberg I, Klein G, Giovanella BC, Stehlin JS, McCormick KJ, Andersson-Anvret M, Aman P and Killander D. Relationship between the amounts of EBV-DNA and EBNA per cell, clonability and tumorigenicity in two EBV-negative lines and their EBV-converted sublines. Intl J Cancer 31(2):163-69, Feb 15 1983.

85. Giavanella BC, Shepard RC, Stehlin JS, Venditti JM and Abbott BJ. Calorie restriction: effect on growth of human tumors heterotransplanted in nude mice.
J Natl Cancer Inst 68(2):249-57, Feb 1982.

84. Morgan AC, Rossen RD, McCormick KJ, Stehlin JS and Giovanella BC. "Hidden" cytotoxic antibodies that react with allogeneic cultured fetal and tumor cells containe in soluble immune complexes from normal human sera. Cancer Res 42(3):881-87, Mar 1982.

83. Evans RA and Stehlin JS. What risk partial mastectomy? [editorial]. Tex Med 77(4):4-6, Apr 1977.

82. Stehlin JS. What's new in cancer surgery? Proc Annu Meet Med Sect Am Counc Life Insur 1981 83-95, 1981.

81. Stehlin JS. Treatment of the primary lesion in melanoma. Surg Gynecol Obstet 152(4):499-500, Apr 1981.

80. McCormick KJ, Giovanella BC, Klein G, Nilsson K and Stehlin JS. Diploid human lymphoblastoid Burkitt lymphoma cell lines: susceptibility to murine NK cells and heterotransplantation to nude mice. Intl J Cancer 28(4):455-58, Oct 15 1981.

79. Stehlin JS, Greeff PJ, Giovanella BC and Williams LJ Jr. Dramatic response of cancer to localized hyperthermia. NY State J Med 80(1):70-72, Jan 1980.

78. Stehlin JS. Hyperthermic perfusion for melanoma of the extremities: experience with 165 patients, 1967 to 1979. Ann NY Acad Sci 335:352-55, 1980.

77. Giovanella BC, Stehlin JS and Yim SO. Correlation of the thermosensitivity of cells to their malignant potential. Ann NY Acad Sci 335:206-14, 1980.

76. Lee SS, Giovanella BC and Stehlin JS. Activity of thymidine as a chemotherapeutic agent against human tumor xenografts in nude mice [letter]. Cancer Res 40(5):1764, May 1980.

75. McCormick KJ, Giovanella BC, Day DC, Parsons WR and Stehlin JS. An enzymatic assay for the detection of natural cytotoxicity. J Immunol Methods 35(1-2):83-90, 1980.

Top of Page

74. Stehlin JS, Giovanella BC, de Ipolyi PD and Anderson RF. Eleven years' experience with hyperthermic perfusion for melanoma of the extremities. World J Surg 3(3):305-07, Jul 1979.

73. Lee SS, Giovanella BC, Stehlin JS and Brunn JC. Regression of human tumors established in nude mice after continuous infusion of thymidine. Cancer Res 39(8):2928-33, Aug 1979.

72. Zaharko DS, Bolten BJ, Kabayashi T, Blasberg RG, Lee SS, Giofanella BC and Stehlin JS. Thymidine and thymine in biologic fluids during high-dose infusion of thymidine in mice, monkeys and man. Cancer Treat Rep 63(6):945-49, Jun 1979.

71. Stehlin JS, Evans RA, Gutierrez AE, Cowles J, de Ipolyi PD and Greeff PJ. Treatment of carcinoma of the breast. Surg Gynecol Obstet 149(6):911-22, Dec 1979.

70. Giovanella BC, Nilsson K, Zech L, Yim SOI, Klein G and Stehlin JS. Growth of diploid, Epstein-Barr virus-carrying human lymphoblastoid cell lines heterotransplanted into nude mice under immunologically privileged onditions. Intl J Cancer 24(1):103-13, Jul 1979.

69. McBride G and Stehlin JS. John Stehlin: holistic oncology and a nude mouse. JAMA 241(13):1321-23, Mar 30, 1979.

68. Stehlin JS, Giovanella BC, de Ipolyi PD and Anderson RF. Results of eleven years' experience with heated perfusion for melanoma of the extremities. Cancer Res 39(6 Pt 2): 2255-2257, Jun 1979.

67. Giovanella BC, Stehlin JS, Shepard RC and Williams LJ Jr. Hyperthermic treatment of human tumors heterotransplanted in nude mice. Cancer Res
39(6 Pt 2):2236-41, Jun 1979.

66. Giovanella BC, Stehlin JS, Williams LJ Jr, Lee SS, and Shepard RC. Heterotrtansplantation of human cancers into nude mice: a model system for human cancer chemotherapy. Cancer 42(5):2269-81, Nov 1978.

65. Stehlin JS. Malignant melanoma: a surgeon's view. J Cont Educ Dermat 15, 1978.

64. Nilsson K, Giovanella BC, Stehlin JS and Klein G. Tumorgenicity of human hematopoetic cell lines in athymic nude mice. Intl J Cancer 19(3):337-44, Mar 1977.

63. Stehlin JS, Giovanella BC, de Ipolyi PD, Muenz LR, Anderson RF and Gutierrez AA. Hyperthermic perfusion of extremities for melanoma and soft tissue sarcomas. Recent Results Cancer Res (59):171-85, 1977.

62. Giovanella BC, Stehlin JS, Santamaria C, Yim SO, Williams LJ Jr, Leibowitz A, Fialkow PJ and Mumford DM. Human Neoplastic and normal cells in tissue culture. I. cell lines derived from malignant melanomas and normal melanocytes.
J Natl Cancer Inst 56(6):1131-42, Jun 1976.

61. Stehlin JS and Giovanella BC. Human cancers grow successfully in nude mice. The Medical Journal of St. Joseph Hospital, Houston, Texas 12(3):99-102, 1977.

60. Lee SS, Giovanella BC and Stehlin JS. Selective lethal effect of thymidine on human and mouse tumor cells. J Cell Physiol 92(3):401-05, Sep 1977.

59. Lee SS, Giovanella BC and Stehlin JS. Effect of excess thymidine on the growth of human melanoma cells transplanted in thymus deficient nude mice. Cancer Lett 3(3-4):209-14, Sep 1977.

58. Giovanella BC, Stehlin JS and Morgan AC. Selective lethal effect of supranormal temperatures on human neoplastic cells. Cancer Res 36(11 Pt 1):3944-50, Nov 1976.

57. Stehlin JS and de Ipolyi PD. Soft tissue sarcomas of the extremity. Multidisciplinary therapy employing hyperthermic perfusion. Am J Surg 130(6):643-46, Dec 1975.

56. Stehlin JS, Giovanella BC, de Ipolyi PD, Muentz L and Anderson RF. Results of hyperthermic perfusion for melanomas of the extremities. Surg Gynecol Obstet 140(3):339-48, 1975.

55. Klein G, Giovanella BC, Westman A, Stehlin JS and Mumford D. An EBV-genome-negative cell line established from an American Burkitt lymphoma: receptor characteristics, EBV infectibility and permanent conversion into EBV-positive sublines by in vitro infection. Intervirology 5(6):319-34, 1975.

54. Klein G, Giovanella BC, Lindahl T, Fialkow PJ, Singh S and Stehlin JS. Direct evidence for the presence of Epstein-Barr virus DNA and nuclear antigen in malignant epithelial cells from patients with poorly differentiated carcinoma of the nasopharynx. Proc Nat Acad Sci 71(12):4737-41, Dec 1974.

53. Stehlin JS, Hafstrom LO and Greeff PJ. Experience with infusion and resection in cancer of the liver. Surg Gynecol Obstet 138(6):855-63, Jun 1974.

52. Giovanella BC, Stehlin JS and Yim SO. Establishment and characterization of a permanent cell line from a human teratocarcinoma. In Vitro 10:382, 1974.

51. Hafstrom LO, Lede RI, Stehlin JS and Brown RO. Influence of hydrocortisone on blood clotting and fibrinolysis after a standard resection of the liver in dogs. Surg Gynecol Obstet 139(6):860-66, Dec 1974.

50. Giovanella BC, Stehlin JS and Williams LJ Jr. Heterotransplantation of human malignant tumors in "nuse" thymusless mice. II. Malignant tumor induced by injection of cell cultures derived from human solid tumors. J Natl Cancer Inst 52(3):921-30, Mar 1974.

Top of Page

49. Giovanella BC, Morgan AC and Stehlin JS and Williams LJ Jr. Selective lethal effect of supranormal temperatures on mouse sarcoma cells. Cancer Res 33(11):2568-78, Nov 1973.

48. Giovanella BC, Yim SO, Morgan AC, Stehlin JS and Williams LJ Jr. Brief communication: metastases of human melanomas transplanted in "nude" mice. J Natl Cancer Inst 50(4):1051-53, Apr 1973.

47. Giovanella BC and Stehlin JS. Heterotransplantation of human malignant tumors in "nude" thymusless mice. J Natl Cancer Inst 51(2):615-19, Aug 1973.

46. Giovanella BC and Stehlin JS. Metastases of human melanomas transplanted in "nude" mice. J Natl Cancer Inst 50:1051-1053, 1973.

45. Giovanella BC, Yim SO, Stehlin JS and Williams, LJ Jr. Development of invasive tumors in the "nude" mouse after injection of cultured human melanoma cells. J Natl st 48(5):1531-33, 1972. Cancer In

44. Stehlin JS. Perfusion of extremities for cancer. Proc Natl Cancer Conf 6:617-20, 1970.

43. Stehlin JS. Regional perfusion for cancer of the extremities. Aktuelle Probl Chir 14:859-63, 1970.

42. Stehlin JS. Hyperthermic perfusion with chemotherapy for cancers of the extremities. Surg Gynecol Obstet 129(2):305-08, Aug 1969.

41. Klatt O, Stehlin JS, McBride C and Griffin AC. The effect of nitrogen mustard treatment on the deoxyribonucleic acid of sensitive and resistant Erlich tumor cells. Cancer Res 29(2):286-290, Feb 1969.

40. Stehlin JS. Malignant melanoma. An appraisal. Surgery 64(6):1149-1157, Dec 1968.

39. Young SE, Griffin AC, Milner AN and Stehlin JS. Free amino acids and related compounds in the blood and urine of patients with malignant melanoma. Cancer Res 27(1):15-17, Jan 1967.

38. Clark RL and Stehlin JS. Perfusion. Regional perfusion technique for melanoma of the extremities. A report on experience with conventional treatment and perfusion in 339 cases. Arq Patol 39(3):115-126, Dec 1967.

37. Stehlin JS, Hills WJ and Rufino C. Disseminated melanoma: biologic behavior and treatment. Arch Surg 94(4):495-501, Apr 1967.

36. Stehlin JS, Rufino C and Hardy RW. Infusion for squamous carcinomas of the hand. Surg Gynecol Obstet 123(4):725-28, Oct 1966.

35. Smith JL and Stehlin JS. Metastatic malignant melanoma in the absence of a primary lesion. Med Rec and Ann 59:67, 1966.

34. Stehlin JS and Beach KG. Psychological aspects of cancer therapy: a surgeon's viewpoint. JAMA 197(2):100-04, Jul 11 1966.

33. Stehlin JS, Smith JL Jr, Jing BD and Sherrin D. Melanomas of the extremities complicated by intransit metastases. Surg Gynecol Obstet 122(1):3-14, Jan 1966.

32. Stehlin JS and Clark RL. Perfusion in melanoma of the extremities. Mod Med 33:166, 1965.

31. Smith JL Jr.and Stehlin JS. Spontaneous regression of primary malignant melanomas with regional metastases. Cancer 18(11):1399-1415, 1965.

30. Stehlin JS and Clark RL. Melanoma of the extremities: experiences with conventional treatment and perfusion in 339 cases. Am J Surg 110:366, 1965.

29. Milner AN, McGee H, Klatt O and Stehlin JS. Alterations in the biochemical composition of body fluids incident to regional chemotherapy. Tex Rep Biol Med 23:81, 1965.

28. Stehlin JS. Perfusion for melanoma of the extremities: Six and one-half years' experience with 221 cases. Proc Natl Cancer Conf 5:525-531, 1964.

27. Stehlin JS. The physician and the incurable patient with cancer. Med Rec and Ann 57:483, 1964.

26. Smith JL Jr, Stehlin JS and Clark RL. Histopathologic changes in malignant melanoma and normal tissue following regional perfusion with l-phenylalanine mustard (sarcolysine). Acta Unio Internationalis Contra Cancrum 20:451, 1964.

25. Stehlin JS, Clark RL, Vickers WE and Monges A. Perfusion for makignant melanoma of the extremities. Am J Surg 105:607, 1963.

Top of Page

24. Stehlin JS. Panel discussion: treatment of melanoma. The pigment cell. NY Acad Sci 100:166, 1963.

23. Chang JP, Russell WO, Stehlin JS and Smith JL Jr. Chemical and histochemical analysis of the tyrosinase activity in melanoma and related lesions. The pigment cell. NY Acad Sci 100:951, 1963.

22. Stehlin JS and Clark RL. Experiences with regional chemotherapy: perfusion and intra-arterial infusion. Arch Surg 85:84, 1962.

21. Stehlin JS, Smith JL Jr and Clark RL. Malignant melanoma: diagnosis and current treatment. Surg Clin North Am 42:455, 1962.

20. Stehlin JS, Clark RL and Dewey WC. Continuous monitoring of leakage during regional perfusion. Arch Surg 83:943, 1961.

19. Rose GG, Jr and Stehlin JS. The golgi complex and melanin elaboration of human melanomas in tissue culture. Canc Res 21:1455, 1961.

18. Stehlin JS and Clark RL. Chemotherapy for cancer by regional perfusion. Arch Surg 83:196, 1961.

17. Stehlin JS, Clark RL, White EC, Healey JE Jr and Smith JL Jr. Hepatic tissue tolerance to the thio-tepa administered by the isolation perfusion technique. J Surg Res 1:111, 1961.

16. Stehlin JS, Clark RL and White EC. Regional perfusion for cancer. Am J Surg 27:400, 1961.

15. Klatt O, Griffin AC and Stehlin JS. A method for determination of phenylalanine mustard and related alkylating agents in blood. Proc Soc Exper Biol and Med 104:629, 1960.

14. Stehlin JS and Clark RL. Perfusion of the extremities: techniques. Cancer Chemotherapy Reports 10:3, 1960.

13. Stehlin JS, Smith JL Jr and Clark RL. Results of perfusion for melanoma. Cancer of the breast a ten-year study of partial mastectomy. Cancer Chemotherapy Reports 10:79, 1960.

12. Healy JD Jr, Smith JL Jr, Clark RL, Stehlin JS and White EC. The effect of thio-tepa upon the liver utilizing a new isolation perfusion technique. Surg Forum 11:11, 1960.

11. Stehlin JS, Clark RL and White EC. Regional chemotherapy via intra-arterial perfusion for the malignant neoplasms. Bull Soc Intl Chir 14:543, 1960.

10. Stehlin JS, Clark RL, White EC, Healey JE Jr, Dewey WC and Beerstecher S: The leakage factor in regional perfusion with chemotherapeutic agents. Arch Surg 80:934, 1960.

9. Stehlin JS, Clark RL, White EC, Smith JL Jr., Griffin AC, Jesse RH Jr and Healey JE. Regional chemotherapy for cancer: experience with 116 perfusions. Ann Surg 151:605, 1960.

8. Stehlin JS, Clark RL, White EC and Smith JL. Malignant melanoma of the extremities: experiences with conventional therapy: a new surgical and chemotherapeutic approach with regional perfusion. Cancer 13:55, 1960.

7. Stehlin JS. Phenylalanine mustard for malignant melanomas. Mod Med 27:95, 1959.

6. Stehlin JS. Transperitoneal lymph node dissection for testicular carcinoma. Mod Med 27:98, 1959.

5. Stehlin JS, Clark RL and White EC. Malignant melanoma problems in clinical management. Am J Surg 25:595, 1959.

4. Stehlin JS, Jones JS, Crigler CM and Creech O. Lymphadenectomy via the transperitoneal (anterior abdominal) approach for cancer of the testis. Am J Surg 97:756, 1959.

3. Stehlin JS. In discussion of paper by Reemtsma K, Ryan RF, Krementz T and Creech O Jr. Treatment of selected adenocarcinomas by perfusion technique. Arch Surg 78:727, 1959.

2. Samuel ML, Stehlin JS, Dale SC and Howe CD. A critical evaluation of numorphan: a new synthetic morphine-like alkaloid. South Med J 52:207, 1959.

1. Erbes J and Stehlin JS. Lymphosarcoma of the cecum causing intussusception in a nine year old boy. Am J Dis Child 85:551, 1953.